Articles tagged with Bleeding
A phase-3 clinical trial has demonstrated the effectiveness of clot-busting therapy in reducing mortality and post-stroke disability in patients with severe intraventricular hemorrhage. The treatment significantly reduced death rates by 10% and improved functional recovery in patients with larger clots.
A phase III clinical trial found that using a cardiac clot-busting drug to treat hemorrhagic strokes safely decreased the death rate by 10 percent. The study also showed that flushing unwanted blood from the brain was associated with better outcomes for many patients, with almost 50 percent living independently at 180 days.
Researchers found that ceria nanoparticles can reduce inflammation in the brain following a bleeding stroke by decreasing the secretion of inflammatory chemicals. In a lab experiment, macrophages treated with ceria nanoparticles showed less damage and water accumulation at the stroke site compared to untreated cells.
Researchers found a high risk of developing dementia after intracerebral hemorrhage, with 20% of patients developing dementia within one year. Risk factors included location of brain bleed, older age, and history of previous stroke.
Researchers have found a significant association between certain oral bacteria and the risk of hemorrhagic stroke. The study suggests that oral health is important for brain health and may play a role in the development of other diseases such as dementia and rheumatoid arthritis.
A proof-of-concept study demonstrates a new method using super-resolution microscopy can accurately diagnose rare platelet disorders, offering an alternative to costly and resource-intensive electron microscopy. This innovative approach provides personalized treatment options, saving the NHS money and improving patient outcomes.
A recent study found that nearly 5,000 trauma patients sustain major haemorrhage each year in England and Wales, with one-third dying due to delays in blood transfusion practices. The study highlights the need for more rapid and consistent delivery of blood components to trauma patients, as this can halve mortality rates.
A new quality measure has been developed to track the variation in colonoscopy quality among outpatient facilities using follow-up hospital visits. The study found that 16.3 per 1,000 outpatient colonoscopies result in unplanned hospital visits, with significant variation across facilities.
A European multicenter study found that intravenous thrombolysis is safe and effective for ischemic stroke patients with preexisting dependency, despite concerns of higher complication rates. The study suggests that these patients should be considered for IVT treatment in randomized-controlled trials.
Researchers have successfully used gene therapy to correct a rare bleeding disorder, factor VII deficiency, in dogs. The treatment showed long-term safety and efficacy, with treated dogs expressing therapeutic levels of clotting factor VII.
A study published in the Journal of the American Society of Hematology found that women on blood thinners can take hormone-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding. The study analyzed data from 1,888 women and showed similar incidence rates of blood clots and a...
Researchers found that transradial rescue PCI was used in only 15% of cases, and those who were most prone to bleeding were more likely to be treated with transfemoral access. The study highlights the 'risk-treatment paradox,' where patients at high risk for a condition are less likely to receive aggressive treatment.
A new antibody called ACE910 has shown promising results in reducing the need for frequent injections in patients with severe hemophilia A. The study found that ACE910 is safe and effective in preventing excessive bleeding, even in patients who develop antibodies to existing treatments.
Researchers at McMaster University have developed an antidote that reverses the effects of two new blood thinners, apixaban and rivaroxaban, within minutes. This breakthrough may help save lives by quickly reversing bleeding complications in emergency situations.
A new study published in the Journal of General Internal Medicine found that hospital patients taking acid-reducing drugs have a higher risk of dying from infections such as pneumonia and C. diff. The simulation model used by researchers found that around 90% of hospital inpatients who were first prescribed these drugs had a higher ris...
A new study published in JAMA Neurology found that loss of consciousness is a common presenting symptom in patients after subarachnoid hemorrhage due to brain aneurysm. The researchers suggest that loss of consciousness may be an indicator of severe bleeding and therefore predict death or poor functional outcome one year later.
Researchers at UBC created a supercharged blood cell called a 'Franken-platelet' by injecting platelets with DNA and other ingredients. The resulting cells produced RNA, which performed as predicted and showed promise for treating bleeding disorders and inflammatory diseases.
A meta-analysis of randomized clinical trials found that endovascular therapy improved functional outcomes and higher rates of independence at 90 days, but no significant difference in symptomatic intracranial hemorrhage or all-cause mortality. The study included data from 8 trials involving 2,423 patients with acute ischemic stroke.
The study analyzed data from 10 US stroke centers and found that treatment of post-thrombolysis brain hemorrhage did not significantly reduce mortality or hematoma expansion. Shortening the time to diagnosis and treatment may be key to improving outcomes.
A study found that primary care physicians often misestimate stroke and bleeding risk in AFib patients, leading to inadequate treatment. This resulted in under- and over-prescription of oral anticoagulation therapy, increasing the risk of stroke and bleeding events.
Researchers have demonstrated the relative safety and effectiveness of eltrombopag in children with persistent immune thrombocytopenia (ITP). The treatment stabilizes platelet counts, enabling children to participate in social activities without frequent nose bleeds.
Pregnant women with rare autoimmune diseases face higher risks of hypertensive disorders, bleeding complications, and preterm births. Infants born to these mothers are also at increased risk of life-threatening conditions, emphasizing the importance of close prenatal care.
Researchers at the University of British Columbia have created a self-propelled powder that can deliver coagulants against severe blood flow to treat trauma-related bleeding. The innovative particles use gas-generating calcium carbonate micro-particles to propel clotting agents deep into damaged tissue.
A CWRU researcher has received a $1.9 million grant to transform synthetic platelet technology into devices that dissolve clots to prevent serious health risks like stroke and heart attack. The technology, called SynthoPlate, has already shown promising results in treating bleeding disorders.
Researchers at Children's Hospital Los Angeles found that an admission hematocrit can identify pediatric patients at high risk for bleeding after injury. The study showed a reliable screening tool with low false negative rate and high specificity.
Patients with inadequate blood pressure control after an intracerebral hemorrhage have a higher risk of recurrence, especially those with worsening hypertension. Systolic and diastolic blood pressures were associated with increased risks of lobar and nonlobar ICH recurrence, respectively.
The XANTUS study found that rivaroxaban is safe and effective for stroke prevention in atrial fibrillation patients with low rates of bleeding and stroke. The study confirmed the positive benefit-risk profile of rivaroxaban established in clinical trials, demonstrating its efficacy and tolerability in real-world practice.
Patients with atrial fibrillation who received antithrombotic management according to ESC guidelines had better outcomes than those who did not. Guideline-adherent patients had significantly lower rates of major adverse events during one year follow up compared to over- or under-treated patients.
Researchers found that patients with high risks of MI and bleeding were admitted for NSTE ACS on warmer, sunnier days with higher carbon monoxide and ozone air concentrations. Treatment with percutaneous coronary intervention (PCI) was more successful when the weather was sunnier but colder and with lower concentrations of air pollutants.
The ESC guidelines now strongly recommend the radial approach over femoral access for coronary angiography and PCI in patients with acute coronary syndromes. The radial approach reduces vascular complications, major bleeding events, and all-cause mortality. Additionally, the guidelines suggest a tailored duration of dual antiplatelet t...
A recent study found that coagulation tests used to monitor internal bleeding in patients taking blood thinners like Xarelto and Eliquis may not be reliable. The tests, such as prothrombin time (PT), PTT, or INR, were found to be elevated in a minority of cases but appear unreliable to measure the risk of internal bleeding.
A study of 900 cancer patients found that heparin treatment did not significantly reduce recurrent blood clots or deaths compared to warfarin, but was associated with lower nonmajor bleeding rates. Heparin was also shown to be safe in this population, supporting its use over warfarin.
Patients on triple therapy had the same rates of adverse cardiac events as dual therapy but experienced more complications and bleeding; researchers recommend reevaluating treatment regimens for this population.
A Phase III trial shows the engineered clotting protein rvWF is safe and effective in controlling bleeding episodes in patients with severe vW disease. The protein increases naturally produced FVIII levels, reducing the need for additional infusions.
A study led by Temple University researchers found that hospitals performing more catheter-directed thrombolysis (CDT) procedures per year had lower mortality rates and bleeding complications. The research, published in the Circulation journal, suggests standardizing CDT protocols can minimize risks at low-volume centers.
A recent study published in The BMJ found that taking a combination of antidepressants and common painkillers increases the risk of bleeding. The researchers analyzed data from over four million patients and found a substantially increased bleeding risk with combined use of antidepressants and NSAIDs, especially in men.
Researchers identified neutrophils as the bloody culprit behind immune cell-induced bleeding. Blocking neutrophil passage could prevent complications in transplant and chemotherapy patients.
Patients with a first episode of pulmonary embolism who received 6 months of anticoagulant treatment showed reduced risk of additional blood clots and major bleeding when treated for an additional 18 months. However, this benefit was not sustained after discontinuation of therapy.
Researchers found that serum S100B levels below 0.105 µg/L are an accurate predictor of no intracranial hemorrhage, reducing the need for costly CCT scans and hospitalizations. This simple blood test may help identify patients who can return home to recover.
A study led by Duke Medicine found that stopping blood thinners before elective surgery has no higher risk of blood clots and less risk of major bleeding compared to traditional 'bridge' therapy.
Researchers found that patients with larger aneurysms or incomplete occlusion face a long-term risk of aneurysm recurrences after endovascular treatment. The study suggests that longer follow-up protocols may be necessary for some intracranial aneurysm patients who undergo EVT.
Researchers at UTSA College of Engineering and US Army Institute of Surgical Research developed a more effective alternative to current standard-of-care platelets for stopping bleeding in injured soldiers. Cold-stored platelets have been shown to retain their energy reserves, making them a viable option for longer storage periods.
For individuals over 75, taking newer anticoagulant medications dabigatran or rivaroxaban increases the risk of gastrointestinal (GI) bleeding by 3-5 times compared to warfarin. The study found that younger patients have a lower risk of GI bleeding with these medications.
A new study finds that carbon monoxide can help accelerate the natural process of clearing heme, a toxic component of red blood cells, and reduce neuronal injury in mice with subarachnoid hemorrhage. The study suggests that low amounts of CO may be used to treat patients with ruptured cerebral aneurysms.
A systematic review of published evidence found that extended dual antiplatelet therapy (DAPT) decreases the risk for myocardial infarction but increases major bleeding events and may increase mortality. The authors suggest based on patient preferences after discussing benefits and harms.
Researchers studied 293 patients with brain metastases and blood clots to determine if administering blood-thinning medication was safe. The study found no significant difference in bleeding risk between patients who received a widely used blood thinner and those who did not.
Current users of menopausal hormone therapy are twice as likely to develop lower gastrointestinal bleeding and ischemic colitis compared to non-users. The study found a higher risk of bleeding in the lower GI tract due to fewer blood vessels supplying this area.
A new system using automated analysis of vital signs during emergency transport has been shown to accurately detect life-threatening bleeding in trauma patients, identifying them 75-80% of the time. This technology could save lives by providing faster care and enabling hospitals to be ready for immediate surgery.
Treatment at comprehensive stroke centers is associated with a 7% reduced risk of death for all hemorrhagic strokes and a 27% reduced risk for subarachnoid hemorrhage. Patients transferred within 24 hours to these centers have a 36% lower mortality rate compared to those remaining in primary care centers or non-stroke centers.
Women with uterine fibroids have several treatment options, including medical and interventional therapies. Alternative treatment options include tranexamic acid, levonorgestrel-releasing IUDs, hysteroscopic myomectomy, endometrial ablation, gonadotropin-releasing hormone agonists, and more.
The 2013 guidelines recommend delivering universal donor plasma to critically injured patients as part of optimized treatment with red blood cell transfusions. This approach can be consistently implemented and rapidly delivered in high-volume trauma centers without excessive wastage.
Researchers compared long-term survival, stroke, reoperation, and bleeding events after bioprosthetic vs mechanical prosthetic mitral valve replacement among 3,433 patients. They found no significant difference in survival at 15 years, but significant differences in risk of reoperation, bleeding, and stroke between the two groups.
Researchers analyzed genomic data from 16,000 individuals to understand the impact of mutations in two genes associated with a blood disorder. They found that about 1.3% carry a mutation in at least one gene, and algorithms predicted varying levels of harm from these mutations.
Researchers at TSRI have identified a molecule, lysophosphatidic acid (LPA), that triggers schizophrenia-like symptoms in animal models, including hyperactivity, anxiety, and altered brain structure. The study provides new tools for preventing or treating psychiatric disorders such as schizophrenia, bipolar disorder, and autism.
A meta-analysis published in The Lancet found that longer dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with increased mortality. Shorter DAPT, on the other hand, was linked to lower rates of all-cause and non-cardiac mortality, as well as reduced risk of major bleeding.
A study of 11,648 patients found that extended dual antiplatelet therapy after bare metal stent placement did not significantly increase rates of stent thrombosis or major adverse cardiac and cerebrovascular events. However, the sample size limitations may have impacted the results, suggesting further trials are needed.
The study found bivalirudin to be associated with significantly lower rates of bleeding complications and death, but failed to meet its co-primary composite endpoints. The high prevalence of heart attacks in patients may have diluted the benefits reflected in the rates of death and bleeding.
Pazopanib, a cancer drug, shows promise in reducing bleeding and small AVMs in patients with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder. The study aims to assess the efficacy of pazopanib in improving symptoms and quality of life for HHT patients.
A novel anti-clotting therapy was compared to established anticoagulants in a Phase III trial, but showed similar efficacy and higher moderate to severe bleeding rates, leading to its early termination due to allergic reactions.
The study found that adding ticagrelor to aspirin therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, with benefits appearing for nearly three years. The trial recruited 21,162 patients and showed a 15% reduction in cardiovascular death with both ticagrelor doses.